Austedo Approved for Treatment of Tardive Dyskinesia


The FDA has approved Austedo (deutetrabenazine, Teva Pharmaceutical Industries Ltd.) tablets for the treatment of tardive dyskinesia in adults. The approval was based on results from two Phase 3 randomized placebo-controlled studies assessing the efficacy and safety of Austedo in reducing the severity of abnormal involuntary movements associated with tardive dyskinesia (AIM-TD and ARM-TD).

Austedo is the second drug approved for the treatment of tardive dyskinesia this year, joining Ingrezza (valbenazine, Neurocrine) as the only two therapies approved for the condition. Austedo was previously approved for the treatment of chorea associated with Huntington’s disease in April 2017.


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in January 2002, Practical Neurology strives to enhance quality of care and improve the daily operation of neurology practices. Each month, our experts explain the real-world significance of recent advances in neurologic science and offer step-by-step advice on how to overcome the clinical and business challenges neurologists face. Our straightforward, how-to articles give neurologists tools they can put into practice right away.